IRadimed Corporation

NASDAQ:IRMD

Medical - Devices

Healthcare
$82.31 +0.73%

+$0.67 today

Market cap
$1.05B
Beta
0.92
P/E (TTM)
49.7
EPS (TTM)
$1.85
Dividend yield
1.35%
52W Low $55.11High $107.90

Volume 0.08M

Average 0.12M

IRMD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

IRadimed CorporationNASDAQ: IRMD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA growth accelerates

Q1 FY2026 EBITDA of $8.22M rose 34.0% year over year, ahead of the +25.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +22.2% a year.

Context

  • EBITDA amounted to 36.7% of revenue in FY2025, up 2.4 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $35.18M (+14.4%) for the fiscal year ending Dec 2026, a slowdown from the +22.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.22M-2.2% QoQ
Last fiscal yearDec 2025
$30.74M+22.5% YoY
LTMMar 2026
$32.23M+25.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.0%-7.9%-41.9 pp
1 year+22.5%+14.4%-8.1 pp
3-year CAGR+22.2%+14.9%-7.3 pp
5-year CAGR+14.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
30.74M USD
Year-over-year change
+22.5%
4-year CAGR
+28.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IRMD compares with its peers on the latest reported figures

  • IRMD's LTM Mar 2026 EBITDA of $32.23M is the 6th highest of the 11 companies compared; the peer median is $22.59M.
  • Its year-over-year change of +25.1% is the 4th highest of 11, against a peer median of -17.5%.
  • EBITDA amounts to 37.4% of revenue for IRMD, versus a peer median of 15.4%.
IRMD Competitors Peer median
EBITDA for IRMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CTEVClaritev CorporationLTM Mar 2026$517.45M +198.9%+44.3%52.9%
AHCOAdaptHealth Corp.LTM Apr 2026$462.48M -25.4%-7.2%16.2%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$173.34M +1.2%+41.4%22.0%
INMDInMode Ltd.LTM Mar 2026$102.9M -26.8%-18.1%27.5%
MDXGMiMedx Group, Inc.LTM Mar 2026$57.26M -9.7%—14.7%
IRMDIRadimed CorporationLTM Mar 2026$32.23M +25.1%+22.2%37.4%
CRONCronos Group Inc.LTM Mar 2026-$12.08M +68.8%—5.9%
AXGNAxoGen, Inc.LTM Sep 2026-$21.24M -198.3%—8.0%
OPKOPKO Health, Inc.LTM Mar 2026-$34.69M -123.1%—6.0%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-$71.9M +52.3%—7.0%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-$289.3M -260.5%—17.6%
Peer median (excluding IRMD) $22.59M-17.5%+17.1%15.4%

Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue41.81M53.3M65.56M73.24M83.81M
Cost of Revenue9.76M12.02M15.4M16.89M19.49M
Gross Profit32.05M41.28M50.16M56.35M64.32M
Gross Margin76.6%77.4%76.5%76.9%76.7%
Research & Development1.91M2.28M2.86M2.83M2.98M
Selling, General & Admin20.33M23.38M27.26M31.55M35.2M
Operating Expenses22.23M25.65M30.12M34.39M38.18M
Depreciation & Amortization1.41M670.67K765.18K817.66K2.38M
EBITDA11.24M16.85M22.5M25.09M30.74M
EBITDA Margin26.9%31.6%34.3%34.3%36.7%
Operating Income9.82M15.63M20.04M21.96M26.15M
Operating Margin23.5%29.3%30.6%30.0%31.2%
Interest Income34.81K581.85K1.86M2.19M0
Interest Expense00000
Other Income / Expenses18.61K553.1K1.7M2.31M2.21M
Income Before Tax9.84M16.18M21.74M24.28M28.36M
Pre-Tax Margin23.5%30.4%33.2%33.1%33.8%
Income Tax Expense510.82K3.35M4.55M5.04M5.88M
Net Income9.33M12.83M17.19M19.23M22.48M
Net Margin22.3%24.1%26.2%26.3%26.8%
EPS (Basic)0.761.021.361.521.77
EPS (Diluted)0.741.021.351.501.75
Weighted Avg Shares12.35M12.56M12.6M12.67M12.72M
Weighted Avg Shares (Diluted)12.59M12.64M12.72M12.78M12.85M

IRadimed Corporation

NASDAQ:IRMD

Intrinsic Alpha fair value

Locked

Current Price

$82.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.